Details for Patent: 9,492,449

Which drugs does patent 9,492,449 protect, and when does it expire?

Patent 9,492,449 protects ZYDELIG and is included in one NDA.

This patent has thirty patent family members in eleven countries.

Summary for Patent: 9,492,449

Title:	Therapies for hematologic malignancies
Abstract:	The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A,
Inventor(s):	W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese, Brian Lannutti, Langdon Miller, Thomas M. Jahn
Assignee:	Gilead Calistoga LLC
Application Number:	US13/417,185
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,492,449
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 9,492,449

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-001	Jul 23, 2014	AB	RX	Yes	No	9,492,449					IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-002	Jul 23, 2014	AB	RX	Yes	Yes	9,492,449					IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

International Family Members for US Patent 9,492,449

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009313878
Australia	2016201634
Australia	2017200837